Cabergoline
Active ingredient: Cabergoline
In short: Cabergoline tablets is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. Limitations of Use Avoid use of cabergoline tablets for the inhibition or suppression of postpartum physiologic lactation because of the r
What is Cabergoline used for?
Cabergoline tablets is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults.
Limitations of Use
Avoid use of cabergoline tablets for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions
.
Cabergoline dosage
Before initiating cabergoline tablets evaluate for valvular heart disease, including with an echocardiogram. If valvular disease is detected, do not administer cabergoline tablets
.
The recommended starting dosage of cabergoline tablets is 0.25 mg orally twice weekly. Titrate cabergoline tablets to achieve normal serum prolactin levels by increasing cabergoline tablets by 0.25 mg orally twice weekly at intervals of no less than 4 weeks. The maximum recommended dosage is 1 mg orally, twice weekly
. Administer cabergoline tablets with or without food
.
If cabergoline tablets is discontinued, monitor the serum prolactin level periodically to determine whether cabergoline tablets should be reinstituted.
How to take Cabergoline — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Fibrotic Conditions
There is a risk of cardiac valvulopathy, and pericardial, pleural, pulmonary, and retroperitoneal fibrosis with cabergoline tablets treatment Advise patients to notify their healthcare provider if they develop shortness of breath, chest pain, persistent cough, difficulty with breathing when lying down, or swelling in their extremities
.
Orthostatic Hypotension
Warn patients about the risk of orthostatic hypotension and instruct patients to rise slowly from a supine or sitting position. Advise patients to notify their healthcare provider if they develop dizziness or lightheadedness
.
Impulse Control Disorders and Compulsive Behaviors
Patients should be alerted to the possibility that patients may experience intense urges to spend money uncontrollably, intense urges to gamble, increased sexual urges, and other intense urges and the inability to control these urges while taking cabergoline tablets. …
Warnings & precautions
Do not take this medicine if: Cabergoline tablets is contraindicated in patients with:
Uncontrolled hypertension.
Known hypersensitivity to ergot derivatives.
History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis, or history of pericardial fibrosis
.
History of pleural, pulmonary, or retroperitoneal fibrotic disorders
.
Before initiating cabergoline tablets, perform a cardiovascular evaluation, including with an echocardiogram, to evaluate for valvular disease. Cabergoline tablets is contraindicated in the presence of valvular disease or pericardial fibrosis
.
Cases of valvular and pericardial fibrosis have often manifested as heart failure. Following cabergoline tablets treatment initiation, monitor for the development of valvulopathy with a cardiac echocardiogram at intervals of 6 to 12 months or as clinically indicated with new onset edema, cardiac murmur, dyspnea, or heart failure. During cabergoline tablets treatment, monitor for chest pain and signs and symptoms of heart failure and if heart failure occurs, valvular fibrosis and pericarditis should be excluded. Consider clinical and diagnostic monitoring such as erythrocyte sedimentation rate, serum creatinine measurements, chest-x- ray, and other investigations and cardiac imaging at baseline and as necessary while patients are treated with during cabergoline tablets treatment. Use cabergoline tablets in patients treated with other drugs associated with valvulopathy only if the potential benefit of cabergoline tablets outweighs the risk.
Discontinue cabergoline tablets if the patient has a new diagnosis of valvular regurgitation, valvular restriction, valve leaflet thickening, or pericarditis. …
Cabergoline side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Cardiac Valvulopathy and Pericardial Fibrosis
.
Pleural, Retroperitoneal, and Pulmonary Fibrosis
.
Orthostatic Hypotension
.
Impulse Control Disorders and Compulsive Behaviors
.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of cabergoline tablets has been evaluated in more than 900 patients with hyperprolactinemic disorders. In a 4-week, double-blind, placebo-controlled trial (Cabergoline tablets vs. placebo)
,
the incidence of the most common adverse reactions during the placebo-controlled trial in patients with hyperprolactinemic disorders is presented in Table 1.
*Adverse reactions that occurred ≥1% in the cabergoline tablets group and frequency more than that reported in the placebo group. …
Drug interactions
Cabergoline tablets, a dopamine receptor agonist, is not recommended for concomitant use with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.
About this medicine
Cabergoline is an ergot derivative and dopamine receptor agonist. The chemical name for cabergoline is 1-[(6-allylergolin-8ß-yl)-carbonyl]-1-[3-(dimethylamino) propyl]-3-ethylurea. Its empirical formula is C
26H
37N
5O
2, and its molecular weight is 451.6. The structural formula is as follows
Cabergoline is a white or almost white crystalline powder freely soluble in alcohol (96%); slightly soluble in 0.1M hydrochloric acid; very slightly soluble in hexane; practically insoluble in water.
Cabergoline tablets, for oral administration, contain 0.5 mg of cabergoline and the inactive ingredients of anhydrous lactose, leucine and magnesium stearate.
How it works: Cabergoline is an ergot derivative and dopamine receptor agonist with a high affinity for D2 receptors. Results of in vitrostudies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. Cabergoline decreased serum prolactin levels in reserpinized rats.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8562f94f-a59a-4893-aefc-ea6547b01e92. Read the full official label on DailyMed.